In patients who have achieved a complete response following definitive concurrent chemoradiotherapy for cervical cancer, there remains limited guidance for follow-up strategies despite a recurrence rate of 10% to 20%.
We assessed the value of meticulous cross-sectional imaging for follow-up and identified subgroups that could benefit from intensive surveillance among those achieving complete response.
